Ausgabe 3/2012
Inhalt (53 Artikel)
Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats
Pius Maliakal, Maen Abdelrahim, Umesh T. Sankpal, Cima Maliakal, Cheryl H. Baker, Stephen Safe, Luis J. Herrera, Ala Abudayyeh, Sumanth Kaja, Riyaz Basha
Caspase-independent apoptosis induction of quorum-sensing autoinducer analogs against chronic myeloid leukemia K562
Masaharu Hazawa, Michiko Kudo, Toshihiro Iwata, Kazuki Saito, Kenji Takahashi, Jun Igarashi, Hiroaki Suga, Ikuo Kashiwakura
Antimetastatic activity and low systemic toxicity of tetradecyl gallate in a preclinical melanoma mouse model
Claudriana Locatelli, Deborah Regina Carvalho, Alessandra Mascarello, Clarissa Amorin Silva de Cordova, Rosendo Augusto Yunes, Ricardo Jose Nunes, Celso Pilati, Tânia Beatriz Creczynski-Pasa
A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines
Jessica Castro, Marc Ribó, Teresa Puig, Ramon Colomer, Maria Vilanova, Antoni Benito
In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83
Xiangrui Liu, Frankie Lam, Shenhua Shi, Peter M. Fischer, Shudong Wang
Inhibition of TGF-β signaling, vasculogenic mimicry and proinflammatory gene expression by isoxanthohumol
Annegret Serwe, Kristina Rudolph, Timm Anke, Gerhard Erkel
Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice
Grace-Ifeyinwa Onimoe, Aiguo Liu, Li Lin, Chang-Ching Wei, Eric B. Schwartz, Deepak Bhasin, Chenglong Li, James R. Fuchs, Pui-kai Li, Peter Houghton, Amanda Termuhlen, Thomas Gross, Jiayuh Lin
Hepatic arterial infusion (HAI) with PEGylated liposomes containing 5-FU improves tumor control of liver metastases in a rat model
Uwe Pohlen, Heinz J. Buhr, Gerd Berger, Jörg-Peter Ritz, Christoph Holmer
Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model
Timothy P. Burkholder, Joshua R. Clayton, Mark E. Rempala, James R. Henry, John M. Knobeloch, David Mendel, Johnathan A. McLean, Yan Hao, David A. Barda, Eileen L. Considine, Mark T. Uhlik, Yuefeng Chen, Liandong Ma, Laura J. Bloem, Jacqueline K. Akunda, Denis J. McCann, Manuel Sanchez-Felix, David K. Clawson, Michael M. Lahn, James J. Starling
DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057
John A. Hartley, Anzu Hamaguchi, Marie Suggitt, Stephen J. Gregson, David E. Thurston, Philip W. Howard
Cell cycle arrest through inhibition of tubulin polymerization by withaphysalin F, a bioactive compound isolated from Acnistus arborescens
Danilo D. Rocha, Aruna Balgi, Ana Isabel V. Maia, Otilia D. Pessoa, Edilberto R. Silveira, Letícia V. Costa-Lotufo, Michel Roberge, Claudia Pessoa
Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2
Alicia A. Goyeneche, Erin E. Seidel, Carlos M. Telleria
In vivo toxicity study of N-1-sulfonylcytosine derivatives and their mechanisms of action in cervical carcinoma cell line
Jelena Kašnar-Šamprec, Ivana Ratkaj, Katarina Mišković, Marina Pavlak, Mirela Baus-Lončar, Sandra Kraljević Pavelić, Ljubica Glavaš-Obrovac, Biserka Žinić
Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genes
Berta Otová, Iwao Ojima, Radka Václavíková, Jiří Hrdý, Marie Ehrlichová, Pavel Souček, Jana Vobořilová, Vlasta Němcová, Ilaria Zanardi, Stanislav Horský, Jan Kovář, Ivan Gut
Aminopyrimidoisoquinolinequinone (APIQ) redox cycling is potentiated by ascorbate and induces oxidative stress leading to necrotic-like cancer cell death
David R. Vásquez, Julien Verrax, Jaime A. Valderrama, Pedro Buc Calderon
A novel synthetic C-1 analogue of 7-deoxypancratistatin induces apoptosis in p53 positive and negative human colorectal cancer cells by targeting the mitochondria: enhancement of activity by tamoxifen
Dennis Ma, Phillip Tremblay, Kevinjeet Mahngar, Pardis Akbari-Asl, Jonathan Collins, Tomas Hudlicky, James McNulty, Siyaram Pandey
Multifunctional 5-aminolevulinic acid prodrugs activating diverse cell-death pathways
Gili Berkovitch-Luria, Michal Weitman, Abraham Nudelman, Ada Rephaeli, Zvi Malik
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design
Amye Tevaarwerk, George Wilding, Jens Eickhoff, Rick Chappell, Carolyn Sidor, Jamie Arnott, Howard Bailey, William Schelman, Glenn Liu
Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma
Masashi Niwakawa, Katsuyoshi Hashine, Raizo Yamaguchi, Hirofumi Fujii, Yasuo Hamamoto, Koichi Fukino, Takahiko Tanigawa, Yoshiteru Sumiyoshi
Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
Yutaka Fujiwara, Naomi Kiyota, Naoko Chayahara, Akiyuki Suzuki, Yoshiko Umeyama, Toru Mukohara, Hironobu Minami
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
Michael Millward, Paul Mainwaring, Alain Mita, Kristine Federico, G. K. Lloyd, Natasha Reddinger, Steffan Nawrocki, Monica Mita, Matthew A. Spear
Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma
Steven J. O’Day, Anna C. Pavlick, Mark R. Albertini, Omid Hamid, Heidi Schalch, Zhihui Lang, Jie Ling, Marielena Mata, Manjula Reddy, Brenda Foster
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
Elwyn C. Cabebe, George A. Fisher, Branimir I. Sikic
A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors
Kyle Holen, Robert DiPaola, Glenn Liu, Antoinette R. Tan, George Wilding, Karl Hsu, Nancy Agrawal, Cong Chen, Lingling Xue, Elizabeth Rosenberg, Mark Stein
A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
Akira Fukutomi, Kiyohiko Hatake, Kaoru Matsui, Sakura Sakajiri, Tomonori Hirashima, Hiromi Tanii, Ken Kobayashi, Nobuyuki Yamamoto
Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia
H. M. Kantarjian, S. Padmanabhan, W. Stock, M. S. Tallman, G. A. Curt, J. Li, A. Osmukhina, K. Wu, D. Huszar, G. Borthukar, S. Faderl, G. Garcia-Manero, T. Kadia, K. Sankhala, O. Odenike, J. K. Altman, M. Minden
Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials
Antonin Levy, Laurence Albiges-Sauvin, Christophe Massard, Hassan Izzedine, Stéphane Edhery, Ratio Bahleda, Carlos Gomez-Roca, Cyrus Chargari, Isabelle Brocheriou-Spelle, Jean-Charles Soria
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
Simona Lapusan, Maria B. Vidriales, Xavier Thomas, Stephane de Botton, Anne Vekhoff, Ruoping Tang, Charles Dumontet, Rodica Morariu-Zamfir, John M. Lambert, Marie-Laure Ozoux, Philippe Poncelet, Jesus F. San Miguel, Ollivier Legrand, Daniel J. DeAngelo, Francis J. Giles, Jean-Pierre Marie
Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non–small cell lung cancer
Isamu Okamoto, Nobuyuki Yamamoto, Kaoru Kubota, Yuichiro Ohe, Naoyuki Nogami, Haruyasu Murakami, Hidetoshi Yamaya, Katsuhiro Ono, Kazuhiko Nakagawa
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
Dirk Strumberg, Beate Schultheis, M. E. Scheulen, R. A. Hilger, J. Krauss, N. Marschner, F. Lordick, F. Bach, D. Reuter, L. Edler, K. Mross
A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer
Xin Zhao, Kai Mei, Xiaohong Cai, Jing Chen, Jingrui Yu, Chengya Zhou, Qiu Li
Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study
Soohyeon Lee, Sang Hyun Yoon, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Hye Jin Choi
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium
Helen J. Mackay, Heather J. Au, Elaine McWhirter, Thierry Alcindor, Andrea Jarvi, Katrina MacAlpine, Lisa Wang, John J. Wright, Amit M. Oza
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research
Do-Youn Oh, Keun Wook Lee, Kyung-Hee Lee, Chang-Hak Sohn, Young Suk Park, Dae Young Zang, Hun-Mo Ryoo, Hong-Suk Song, Jin-Soo Kim, Hye-Jin Kang, Bong-Seog Kim, Yung-Jue Bang
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer
A. B. El-Khoueiry, R. K. Ramanathan, D. Y. Yang, W. Zhang, S. Shibata, J. J. Wright, D. Gandara, H. J. Lenz
Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group)
Beate Schultheis, Dirk Strumberg, Lothar Bergmann, Ullrich Graeven, Axel-Rainer Hanauske, Rainer Lipp, Jochen Schuette, K. Saito, Paul Scigalla, Max E. Scheulen
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials
Axel Le Cesne, Alejandro Yovine, Jean-Yves Blay, Suzette Delaloge, Robert G. Maki, Jean-Louis Misset, Pilar Frontelo, Antonio Nieto, Juhui James Jiao, George D. Demetri
A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer
Daniel J. Renouf, Patricia A. Tang, Pierre Major, Monika K. Krzyzanowska, Bindi Dhesy-Thind, John R. Goffin, David Hedley, Lisa Wang, L. Doyle, Malcolm J. Moore
The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan
Marije Slingerland, Hans Gelderblom
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
Manish R. Sharma, Kristen Wroblewski, Blase N. Polite, James A. Knost, James A. Wallace, Sanjiv Modi, Bethany G. Sleckman, David Taber, Everett E. Vokes, Walter M. Stadler, Hedy L. Kindler
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
György Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella, Tudor Eliade Ciuleanu, G. Pover, N. C. Tebbutt
Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
Kohei Shitara, Junko Ikeda, Tomoya Yokota, Daisuke Takahari, Takashi Ura, Kei Muro, Keitaro Matsuo
A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia
Craig Reynolds, Nicholas Di Bella, Roger M. Lyons, William Hyman, Donald A. Richards, Gerald J. Robbins, Mark Vellek, Kristi A. Boehm, Feng Zhan, Lina Asmar
Further developments for improving response and tolerance to irradiation for advanced renal cancer: concurrent (mTOR) inhibitor RAD001 and helical tomotherapy
Youlia M. Kirova, Vincent Servois, Cyrus Chargari, Malika Amessis, Marc Zerbib, Philippe Beuzeboc
Everolimus-related organizing pneumonia: a report establishing causality
Justine Frija, Dominique Joly, Bertrand Knebelmann, Daniel Dusser, Pierre-Régis Burgel
Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells
David Davidson, Yannick Coulombe, Veronica L. Martinez-Marignac, Lilian Amrein, Jeremy Grenier, Keira Hodkinson, Jean-Yves Masson, Raquel Aloyz, Lawrence Panasci
TRAIL shows potential cardioprotective activity
Barbara Toffoli, Stella Bernardi, Riccardo Candido, Serena Zacchigna, Bruno Fabris, Paola Secchiero
Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor
Edgardo S. Santos, Jorge E. Gomez, Luis E. Raez
Erratum to: Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model
Timothy P. Burkholder, Joshua R. Clayton, Mark E. Rempala, James R. Henry, John M. Knobeloch, David Mendel, Johnathan A. McLean, Yan Hao, David A. Barda, Eileen L. Considine, Mark T. Uhlik, Yuefeng Chen, Liandong Ma, Laura J. Bloem, Jacqueline K. Akunda, Denis J. McCann, Manuel Sanchez-Felix, David K. Clawson, Michael M. Lahn, James J. Starling
Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
György Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella, Tudor Eliade Ciuleanu, G. Pover, N. C. Tebbutt
Erratum to: Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma
Masashi Niwakawa, Katsuyoshi Hashine, Raizo Yamaguchi, Hirofumi Fujii, Yasuo Hamamoto, Koichi Fukino, Takahiko Tanigawa, Yoshiteru Sumiyoshi
Erratum to: Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials
Antonin Levy, Laurence Albiges-Sauvin, Christophe Massard, Hassan Izzedine, Stéphane Ederhy, Ratio Bahleda, Carlos Gomez-Roca, Cyrus Chargari, Isabelle Brocheriou-Spelle, Jean-Charles Soria
Erratum to: Nimbolide a limonoid from Azadirachta indica inhibits proliferation and induces apoptosis of human choriocarcinoma (BeWo) cells
G. Harish Kumar, K. V. P. Chandra Mohan, A. Jagannadha Rao, S. Nagini